Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA Aigner

Expert Opinion on Biological Therapy

Volumn 9, Issue 12, 2009, Pages 1533-1542

  Aigner, Achim ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bacteria mediated RNAi; Bm RNAi; RNA interference; RNAi; ShRNA; SiRNA; Therapeutic RNA; TkRNAi; Transkingdom RNAi

Indexed keywords

SHORT HAIRPIN RNA;

BACTERIAL INFECTION; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SALMONELLA TYPHIMURIUM; TARGET CELL; TUMOR CELL;

ANIMALS; BACTERIA; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; RNA INTERFERENCE; RNA, BACTERIAL; RNA, SMALL INTERFERING;

BACTERIA (MICROORGANISMS);

EID: 70450179734     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903307354     Document Type: Review

References (84)

1. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990;2(4):279-289
2. Romano N, Macino G. Quelling: Transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol Microbiol 1992;6(22):3343-3353
3. Guo S, Kemphues KJ. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 1995;81(4):611-620
4. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 1998;391(6669):806-811 (Pubitemid 28099681)
5. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in drosophila cells. Nature 2000;404(6775):293-296
6. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-498
7. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-297
8. Nicoloso MS, Spizzo R, Shimizu M, et al. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009;9(4):293-302
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857-866
10. Garzon R, Fabbri M, Cimmino A, et al. MicroRNA expression and function in cancer. Trends Mol Med 2006;12(12):580-587
11. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15(2):188-200 (Pubitemid 32107664)
12. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999;286(5441):950-952
13. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409(6818):363-366
14. Martinez J, Patkaniowska A, Urlaub H, et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002;110(5):563-574
15. Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004;305(5689):1437-1441
16. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005;123(4):631-640
17. Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003;42(26):7967-7975
18. Chiu YL, Rana TM. siRNA function in RNAi: A chemical modification analysis. RNA 2003;9(9):1034-1048
19. Sohail M, Doran G, Riedemann J, et al. A simple and cost-effective method for producing small interfering RNAs with high efficacy. Nucleic Acids Res 2003;31(7):e38. Published online 7 February 2003, doi: 10.1093/nar/gng038
20. Donze O, Picard D. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 2002;30(10):e46
21. Kim DH, Longo M, Han Y, et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004;22(3):321-325
22. Aigner A. Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des 2008;14(34):3603-3619
23. Sioud M. RNA interference and innate immunity. Adv Drug Deliv Rev 2007;59(2-3):153-163
24. Aigner A. Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr Opin Mol Ther 2007;9(4):345-352
25. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296(5567):550-553
26. Paddison PJ, Caudy AA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16(8):948-958
27. Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 2003;13(2):83-105
28. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002;20(5):500-505
29. Mao Y, Mello C, Lamarcq L, et al. Viral delivery of shRNA. In: Appasani K, editor, RNA interference technology. Cambridge, UK: Cambridge University Press; 2004. p. 161-173
30. Li CX, Parker A, Menocal E, et al. Delivery of RNA interference. Cell Cycle 2006;5(18):2103-2109
31. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441(7092):537-541
32. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118(9):3132-3142
33. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348(3):255-256
34. Xiang R, Mizutani N, Luo Y, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005;65(2):553-561
35. Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum Gene Ther 2001;12(12):1594-1596
36. King I, Bermudes D, Lin S, et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum Gene Ther 2002;13(10):1225-1233
37. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003;4(9):548-556
38. Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. Bioessays 2006;28(1):84-94
39. Wei MQ, Ellem KA, Dunn P, et al. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer 2007;43(3):490-496
40. Xiang S, Fruehauf J, Li CJ. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 2006;24(6):697-702
41. Isberg RR, Voorhis DL, Falkow S. Identification of invasin: A protein that allows enteric bacteria to penetrate cultured mammalian cells. Cell 1987;50(5):769-778
42. Young VB, Falkow S, Schoolnik GK. The invasin protein of Yersinia enterocolitica: Internalization of invasin-bearing bacteria by eukaryotic cells is associated with reorganization of the cytoskeleton. J Cell Biol 1992;116(1):197-207
43. Courvalin P, Goussard S, Grillot-Courvalin C. Gene transfer from bacteria to mammalian cells. Comptes rendus de l'Academie des sciences 1995;318(12):1207-1212
44. Grillot-Courvalin C, Goussard S, Huetz F, et al. Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol 1998;16(9):862-866
45. Mathew E, Hardee GE, Bennett CF, Lee KD. Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes. Gene Ther 2003;10(13):1105-1115
46. Kim TH, Xiong H, Zhang Z, Ren B. Beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 2005;24(4):597-604
47. Nguyen T, Fruehauf J. Bacterial vectors for RNAi delivery. In: Slator R, Hill C, editors, Patho-Biotechnology. Austin, TX, USA: Landes Bioscience and Springer Science; 2008. p. 121-125
48. Hense M, Domann E, Krusch S, et al. Eukaryotic expression plasmid transfer from the intracellular bacterium Listeria monocytogenes to host cells. Cell Microbiol 2001;3(9):599-609
49. Weiss S, Chakraborty T. Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. Curr Opin Biotechnol 2001;12(5):467-472 (Pubitemid 32972171)
50. Bermudes D, Zheng LM, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors. Curr Opin Drug Discov Devel 2002;5(2):194-199
51. Paglia P, Terrazzini N, Schulze K, et al. In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery. Gene Ther 2000;7(20):1725-1730
52. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981;291(5812):238-239
53. Pawelek JM, Low KB, Bermudes D. Tumor-targeted salmonella as a novel anticancer vector. Cancer Res 1997;57(20):4537-4544
54. Low KB, Ittensohn M, Le T, et al. Lipid A mutant salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999;17(1):37-41
55. Zhang L, Gao L, Zhao L, et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 2007;67(12):5859-5864
56. Miller SI, Kukral AM, Mekalanos JJ. A two-component regulatory system (phoP phoQ) controls salmonella typhimurium virulence. Proc Natl Acad Sci USA 1989;86(13):5054-5058
57. Groisman EA, Chiao E, Lipps CJ, Heffron F. Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc Natl Acad Sci USA 1989;86(18):7077-7081
58. Galan JE, Curtiss R 3rd. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb Pathog 1989;6(6):433-443
59. Fields PI, Swanson RV, Haidaris CG, Heffron F. Mutants of salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc Natl Acad Sci USA 1986;83(14):5189-5193
60. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted salmonella enterica serovar typhimurium expressing helicobacter pylori urease in adult volunteers. Infect Immun 2000;68(4):2135-2141
61. Tjuvajev J, Blasberg R, Luo X, et al. Salmonella-based tumor-targeted cancer therapy: Tumor amplified protein expression therapy (TAPET) for diagnostic imaging. J Control Release 2001;74(1-3):313-315
62. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Curr Opin Oncol 1999;11(6):490-496
63. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62(22):6659-6666
64. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10(1):39-49
65. Chen Z, Han ZC. STAT3: A critical transcription activator in angiogenesis. Med Res Rev 2008;28(2):185-200
66. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18(2):254-267
67. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008;15(9):834-843
68. Barnich N, Hisamatsu T, Aguirre JE, et al. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem 2005;280(19):19021-19026
69. Lufei C, Ma J, Huang G, et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 2003;22(6):1325-1335
70. Zhang J, Yang J, Roy SK, et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 2003;100(16):9342-9347
71. Zhao HF, L'Abbe D, Jolicoeur N, et al. High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion. Nat Methods 2005;2(12):967-973
72. Aouadi M, Tesz GJ, Nicoloro SM, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458(7242):1180- 1184
73. Siolas D, Lerner C, Burchard J, et al. Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 2005;23(2):227-231
74. Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005;23(2):222-226
75. John M, Constien R, Akinc A, et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007;449(7163):745-747
76. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137(6):1005-1017
77. Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing salmonella typhimurium. Proc Natl Acad Sci USA 2005;102(3):755-760 (Pubitemid 40282738)
78. Zhao M, Yang M, Ma H, et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006;66(15):7647-7652
79. Zheng LM, Luo X, Feng M, et al. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol Res 2001;12(3):127-135
80. Chatfield SN, Charles IG, Makoff AJ, et al. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: Development of a single-dose oral tetanus vaccine. Biotechnology (NY) 1992;10(8):888-892
81. DiPetrillo MD, Tibbetts T, Kleanthous H, et al. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing helicobacter pylori urease in adult volunteers. Vaccine 1999;18(5-6):449-459
82. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996;173(6):1408-1414
83. Sirard JC, Niedergang F, Kraehenbuhl JP. Live attenuated salmonella: A paradigm of mucosal vaccines. Immunol Rev 1999;171:5-26
84. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20(1):142-152